Tethys BioScience Inc.
This article was originally published in Start Up
Executive Summary
In diabetes, Tethys BioScience has a commercial objective different than most. Many biotech and pharmaceutical firms are working on drugs to treat the disorder or its side effects, to stave it off or even just reduce the amount of insulin a diabetic needs to inject. Tethys parts from the crowd with a brand-new way of testing for diabetes risk. It aims to thereby capture $500 million in sales annually-at least. The Tethys approach involves a panel of seven biomarkers.
You may also be interested in...
Start-Up Previews (11/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibody Start-Ups," features profiles of 4-Antibody, Anaptys Biosciences and f-star. Plus these Start-Ups Across Health Care: Actuality Medical, INBONE Technologies, Interrad Medical and Tethys BioScience.
Start-Up Previews (11/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibody Start-Ups," features profiles of 4-Antibody, Anaptys Biosciences and f-star. Plus these Start-Ups Across Health Care: Actuality Medical, INBONE Technologies, Interrad Medical and Tethys BioScience.
Does Roche Have It Right?
Roche's hostile tender offer for Ventana Medical Systems, and to a lesser extent its recent acquisitions of life science tools companies this year, highlight the firm's belief in diagnostics and its bet that personalized medicine--an area where innovative platforms and molecular test content will play significant if separate roles--will be key to its long-term growth. It could be an expensive and risky strategy that will take years to come to fruition.